RxDoctor Payments Data

April Dillion-Bialobrzeski, DO

Family Medicine · Boise, IDNPI 1033329842

Payments from drug & device makers

$1,412in general payments, 2019–2025

Across 79 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$288
  • AbbVie$200
  • Boehringer Ingelheim$137
  • Amgen$121
  • GSK$115
  • Pfizer$108
  • plus $444 from 14 others

What the payments were for

  • Food & beverage$1,39499%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,412 in reported general payments places this provider in the 75th percentile of 803 family medicine providers in Idaho.

See all family medicine providers in Idaho

Medicare billing

Part B allowed, 2024
$48,159
Medicare patients
114
Services billed
607

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$34,221
MounjaroTirzepatide23$33,987
EliquisApixaban22$31,023
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr31$25,166
FarxigaDapagliflozin Propanediol27$23,511
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$22,598
XareltoRivaroxaban16$16,443
RybelsusSemaglutide13$14,036
JardianceEmpagliflozin18$13,020
Aimovig AutoinjectorErenumab-Aooe13$9,487
Breo ElliptaFluticasone/Vilanterol12$4,682
Rosuvastatin Calcium307$3,461
Estradiol59$3,190
Levothyroxine Sodium211$2,235
Omeprazole101$1,828

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta$115$52,44660 claims
Novo NordiskOzempic, Rybelsus$65$48,25730 claims
Lilly USA, LLCMounjaro$103$33,98723 claims
PfizerEliquis$108$31,02322 claims
AstraZenecaFarxiga$288$23,51127 claims
Boehringer IngelheimJardiance$137$13,02018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 803 family medicine providers in Idaho.

Other family medicine in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →